Categories: Health

EssilorLuxottica: Third-Quarter 2025 Revenue Conference Call Invitation

Third-Quarter 2025 Revenue
Conference Call Invitation

Mr STEFANO GRASSI, Chief Financial Officer, and
Mr GIORGIO IANNELLA, Head of Investor Relations,
have the pleasure of inviting you to our Third-Quarter 2025 Revenue Conference Call on:

Thursday, October 16, 2025, at 6:30 pm CEST

Dial-in telephone access:

If you wish to dial into the conference call, please pre-register at the following link to receive the personal credentials (Dial-in numbers, Conference ID and User ID):

https://grid.trustwavetechnology.com/essilorluxottica/register.html

If you encounter any issue in the pre-registration phase you may contact ir@essilorluxottica.com, providing your name and surname and the name of your company.

Live webcast:

You can watch the presentation at the following link:

https://streamstudio.world-television.com/1217-2090-42396/en

The press release will be published at 6:00 pm CEST on the same day and the presentation slides will be made available prior to the call. Both can be found on https://www.essilorluxottica.com/investors.

GlobeNews Wire

Recent Posts

Deepak Group Goes Beyond Green with hands-On Mangrove Restoration

Deepak Group undertakes mangrove plantation drive on World Environment DaySustainable restoration along the Paniyadra coast,…

21 minutes ago

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction,…

4 hours ago

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as…

4 hours ago

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)…

4 hours ago

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

June 05, 2026 20:13 ET  | Source: Bluejay Diagnostics, Inc. $8.5 million upfront with up…

4 hours ago